NCT06412562

Brief Summary

Low mood and anhedonia represent the fundamental symptoms of major depressive disorder (MDD). Nevertheless, there is currently no standardized visual analogue scale available to assess the extent of both symptoms concurrently. The Maudsley 3-item Visual Analogue Scale (M3VAS) is a newly developed tool for participants to self-assess core symptoms of depression: mood quality, pleasure experience (anhedonia), and suicidality. Despite suicidality not being a primary symptom, it is included due to its critical relevance to safety. Participants will be instructed to rate the intensity and frequency of their experiences over the preceding two weeks by marking a 100 mm ungraded line. A researcher will then assign a numerical value based on the mark's position, utilizing the left edge as 0 and the right as 100. The total score range, combining the three symptoms, ranged from 0 (minimum) to 300 (maximum). The M3VAS exhibited good psychometric properties in British population. In this study, the objective is to assess the psychometric properties of the scale within the Polish population diagnosed with major depressive episode within major depressive disorder or bipolar disorder.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
4mo left

Started May 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
May 2024Sep 2026

First Submitted

Initial submission to the registry

May 9, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

May 9, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 14, 2024

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

May 14, 2024

Status Verified

May 1, 2024

Enrollment Period

2.3 years

First QC Date

May 9, 2024

Last Update Submit

May 9, 2024

Conditions

Keywords

anhedonia; low mood; suicidality; depression; m3vas

Outcome Measures

Primary Outcomes (1)

  • The Maudsley 3-item Visual Analogue Scale (M3VAS)

    To analyze internal consistency and factor analysis

    Baseline

Secondary Outcomes (1)

  • 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16)

    Baseline

Study Arms (1)

Major Depressive Episode

Patients must have a Diagnostic and Statistical Manual 5 (DSM-5) diagnosis of Major Depressive Disorder (MDD) or Bipolar Disorder (BD), as determined by a psychiatrist.

Diagnostic Test: The Maudsley 3-item Visual Analogue Scale (M3VAS)

Interventions

Patients will be asked to complete The Maudsley 3-item Visual Analogue Scale (M3VAS) and 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16).

Also known as: 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16)
Major Depressive Episode

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Inpatients referred to the tertiary-reference unit for mood disorders with MDD or BD diagnosis, currently either with current depression or euthymic

You may qualify if:

  • Diagnosis as provided by DSM-5 criteria:
  • Major depressive disorder (MDD) Bipolar disorder (BD)

You may not qualify if:

  • Diagnosis as provided by DSM-5 criteria:
  • Psychotic disorders Current Mania or hypomania within bipolar disorder (BD)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Gdańsk

Gdansk, Poland

RECRUITING

Related Publications (1)

  • Moulton CD, Strawbridge R, Tsapekos D, Oprea E, Carter B, Hayes C, Cleare AJ, Marwood L, Mantingh T, Young AH. The Maudsley 3-item Visual Analogue Scale (M3VAS): Validation of a scale measuring core symptoms of depression. J Affect Disord. 2021 Mar 1;282:280-283. doi: 10.1016/j.jad.2020.12.185. Epub 2020 Dec 31.

    PMID: 33418379BACKGROUND

MeSH Terms

Conditions

Depressive DisorderAnhedoniaConsciousness DisordersSuicidal IdeationDepression

Condition Hierarchy (Ancestors)

Mood DisordersMental DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersSuicideSelf-Injurious BehaviorBehavioral SymptomsBehavior

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 9, 2024

First Posted

May 14, 2024

Study Start

May 9, 2024

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

May 14, 2024

Record last verified: 2024-05

Locations